Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Training experts in antigen processing to deliver new drug prototypes for cancer and autoimmune diseases

Descrizione del progetto

Nuovi spunti sull’elaborazione antigenica nell’autoimmunità e nel cancro

Prove sempre più numerose indicano che gli enzimi ERAP scindono proteine per generare peptidi antigenici da presentare al sistema immunitario. Questi enzimi costituiscono quindi obiettivi interessanti per modulare il sistema immunitario nella lotta contro le malattie autoimmuni e il cancro. Il progetto CAPSTONE, finanziato dall’UE, si propone di studiare i meccanismi di fondo della disfunzione nell’elaborazione antigenica che si verifica in queste malattie e il coinvolgimento degli enzimi ERAP. Con l’obiettivo sul lungo termine di sviluppare farmaci terapeutici innovativi, CAPSTONE riunirà un gruppo di esperti intersettoriale e multidisciplinare. Cosa ancora più importante, formerà ricercatori in fase iniziale e li preparerà per una carriera nel mondo accademico o nell’industria farmaceutica.

Obiettivo

Current trends in immunotherapy are to develop immuno-modulatory small molecules for intracellular targets for single therapy or combination with existing treatments. CAPSTONE scientists have recently identified the key pathway of intracellular antigen processing for modulating the immune response. ERAP enzymes that generate antigenic peptides have thus emerged as promising targets for the cancer immunotherapy and autoimmune diseases treatments. Our innovative research approach based on ERAP, targets the upstream molecular events that cause these diseases. We aim at fully understanding this pathway, deciphering the mechanisms of antigen processing dysfunctions in diseases, and developing innovative therapeutic drugs. This will provide unique opportunities for future treatment of unmet medical needs and innovative immunotherapies. CAPSTONE will thus be an excellent scientific environment to train the next generation of 15 Early Stage Researchers (ESRs) and establish an innovative cross-fertilisation between oncology and auto-immunity. Our fellows will be able to perform outstanding research at the forefront of transdisciplinary science within a high-calibre international network of academics, industries and patient associations. CAPSTONE brings together an intersectorial and multidisciplinary group of researchers in medicinal chemistry, X-Ray crystallography, cellular biology, oncology, autoimmunity, bioanalysis, mass spectrometry imaging, formulation, systems biology, personalised medicine that will expose the ESRs to key R&D stages, from basic research to pre-clinical development. CAPSTONE will prepare the ESRs for exciting career perspectives in academia, the pharmaceutical industry, biotechnology SMEs, and provide them with scientific and transferable skills and high-value professional connections. Industrial secondments and public engagement will add to a broad skill set to ensure employability in the higher ranks of academia and industry.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Coordinatore

UNIVERSITE DE LILLE
Contribution nette de l'UE
€ 549 604,08
Indirizzo
42 RUE PAUL DUEZ
59000 Lille
Francia

Mostra sulla mappa

Regione
Hauts-de-France Nord-Pas de Calais Nord
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 549 604,08

Partecipanti (9)